October 1, 2022 Share Click to Access Audio Press Release CHICAGO, Oct. 1, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the primary results from the Phase 1/2 study evaluating the investigational gene th...
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding botaretigene sparoparvovec and JNJ-81201887. The reader is cautioned not to rely on these forward-looking state...